Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 14, 2014; 20(30): 10628-10636
Published online Aug 14, 2014. doi: 10.3748/wjg.v20.i30.10628
Published online Aug 14, 2014. doi: 10.3748/wjg.v20.i30.10628
Selection of treatment modalities for Budd-Chiari Syndrome in China: A preliminary survey of published literature
Xing-Shun Qi, Wei-Rong Ren, Dai-Ming Fan, Guo-Hong Han, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an 710000, Shaanxi Province, China
Xing-Shun Qi, Department of Gastroenterology, General Hospital of Shenyang Military Area, Shenyang 110840, Liaoning Province, China
Xing-Shun Qi, Department of Gastroenterology, No. 463 Hospital of Chinese PLA, Shenyang 110000, Liaoning Province, China
Author contributions: Qi XS designed the work; Qi XS and Ren WR collected the data; Qi XS, Ren WR, Fan DM and Han GH analyzed and interpreted the data; Qi XS drafted the manuscript; Fan DM and Han GH made critical revision of the manuscript; Qi XS and Ren WR contributed equally to this work.
Correspondence to: Guo-Hong Han, Professor, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, No. 27 West Changle Road, Xi’an 710032, Shaanxi Province, China. guohhan@126.com
Telephone: +86-29-84771537 Fax: +86-29-82539041
Received: December 19, 2013
Revised: March 29, 2014
Accepted: April 30, 2014
Published online: August 14, 2014
Revised: March 29, 2014
Accepted: April 30, 2014
Published online: August 14, 2014
Core Tip
Core tip: This preliminary survey of published literature demonstrated that the selection of treatment modalities for Budd-Chiari syndrome (BCS) might be different between China and Western countries. Balloon angioplasty with or without stenting, also known as percutaneous recanalization, was the most common treatment modality for BCS in China.